Cullen Frost Bankers Inc. Has $292,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Cullen Frost Bankers Inc. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 91.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 519 shares of the biopharmaceutical company’s stock after selling 5,904 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Regeneron Pharmaceuticals were worth $292,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dodge & Cox boosted its holdings in Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $628,151,000. Acadian Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 234.7% in the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after buying an additional 326,583 shares during the period. Loomis Sayles & Co. L P grew its position in Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Regeneron Pharmaceuticals by 26.5% during the second quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock valued at $564,808,000 after acquiring an additional 225,078 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 1.1%

Shares of Regeneron Pharmaceuticals stock opened at $771.25 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The stock has a market capitalization of $81.06 billion, a P/E ratio of 18.47, a price-to-earnings-growth ratio of 1.99 and a beta of 0.39. The company has a 50-day simple moving average of $757.47 and a 200 day simple moving average of $647.23. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $12.46 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on REGN. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $627.00 to $860.00 in a research report on Wednesday, January 7th. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Scotiabank lifted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Citigroup increased their price objective on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $784.77.

Insider Activity at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.